Comprehensive Assessment of TP53 Loss of Function Using Multiple Combinatorial Mutagenesis Libraries

Overview

Journal Sci Rep

Specialty Science

Date 2020 Nov 24

PMID 33230179

Citations 10

Authors

Vincent Carbonnier

Bernard Leroy

Shai Rosenberg

Thierry Soussi

Affiliations

Soon will be listed here.

Abstract

The diagnosis of somatic and germline TP53 mutations in human tumors or in individuals prone to various types of cancer has now reached the clinic. To increase the accuracy of the prediction of TP53 variant pathogenicity, we gathered functional data from three independent large-scale saturation mutagenesis screening studies with experimental data for more than 10,000 TP53 variants performed in different settings (yeast or mammalian) and with different readouts (transcription, growth arrest or apoptosis). Correlation analysis and multidimensional scaling showed excellent agreement between all these variables. Furthermore, we found that some missense mutations localized in TP53 exons led to impaired TP53 splicing as shown by an analysis of the TP53 expression data from the cancer genome atlas. With the increasing availability of genomic, transcriptomic and proteomic data, it is essential to employ both protein and RNA prediction to accurately define variant pathogenicity.

Citing Articles

Mis-splicing drives loss of function of p53E224D point mutation.

Lock I, Leisenring N, Floyd W, Xu E, Luo L, Ma Y PLoS One. 2025; 20(3):e0318856.

PMID: 40043089 PMC: 11882087. DOI: 10.1371/journal.pone.0318856.

Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations.

Funk J, Klimovich M, Drangenstein D, Pielhoop O, Hunold P, Borowek A Nat Genet. 2025; 57(1):140-153.

PMID: 39774325 PMC: 11735402. DOI: 10.1038/s41588-024-02039-4.

TP53: the unluckiest of genes?.

Joerger A, Stiewe T, Soussi T Cell Death Differ. 2024; 32(2):219-224.

PMID: 39443700 PMC: 11803090. DOI: 10.1038/s41418-024-01391-6.

Cancer associated variant enrichment CAVE, a gene agnostic approach to identify low burden variants in chronic lymphocytic leukemia.

Yaacov A, Lazarian G, Pandzic T, Westrom S, Baliakas P, Imache S Sci Rep. 2024; 14(1):21962.

PMID: 39304718 PMC: 11415367. DOI: 10.1038/s41598-024-73027-1.

Germline p.R181H variant in TP53 in a family exemplifying the genotype-phenotype correlations in Li-Fraumeni syndrome.

Freycon C, Palma L, Budd C, Coulombe F, Witkowski L, Hainaut P Fam Cancer. 2024; 23(4):665-669.

PMID: 39261343 DOI: 10.1007/s10689-024-00419-7.

References

Donehower L, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M . Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Rep. 2019; 28(5):1370-1384.e5. PMC: 7546539. DOI: 10.1016/j.celrep.2019.07.001. View

Bonnal S, Lopez-Oreja I, Valcarcel J . Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020; 17(8):457-474. DOI: 10.1038/s41571-020-0350-x. View

Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B . Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors. Proc Natl Acad Sci U S A. 2012; 109(24):9551-6. PMC: 3386058. DOI: 10.1073/pnas.1200019109. View

Leroy B, Ballinger M, Baran-Marszak F, Bond G, Braithwaite A, Concin N . Recommended Guidelines for Validation, Quality Control, and Reporting of Variants in Clinical Practice. Cancer Res. 2017; 77(6):1250-1260. PMC: 7457206. DOI: 10.1158/0008-5472.CAN-16-2179. View

Supek F, Minana B, Valcarcel J, Gabaldon T, Lehner B . Synonymous mutations frequently act as driver mutations in human cancers. Cell. 2014; 156(6):1324-1335. DOI: 10.1016/j.cell.2014.01.051. View

Boettcher S, Miller P, Sharma R, McConkey M, Leventhal M, Krivtsov A . A dominant-negative effect drives selection of missense mutations in myeloid malignancies. Science. 2019; 365(6453):599-604. PMC: 7327437. DOI: 10.1126/science.aax3649. View

Kotler E, Shani O, Goldfeld G, Lotan-Pompan M, Tarcic O, Gershoni A . A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation. Mol Cell. 2018; 71(1):178-190.e8. DOI: 10.1016/j.molcel.2018.06.012. View

Neskey D, Osman A, Ow T, Katsonis P, McDonald T, Hicks S . Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res. 2015; 75(7):1527-36. PMC: 4383697. DOI: 10.1158/0008-5472.CAN-14-2735. View

Michalak E, Villunger A, Adams J, Strasser A . In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ. 2008; 15(6):1019-29. PMC: 2974267. DOI: 10.1038/cdd.2008.16. View

10.

Schlereth K, Beinoraviciute-Kellner R, Zeitlinger M, Bretz A, Sauer M, Charles J . DNA binding cooperativity of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell. 2010; 38(3):356-68. DOI: 10.1016/j.molcel.2010.02.037. View

11.

Kato S, Han S, Liu W, Otsuka K, Shibata H, Kanamaru R . Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A. 2003; 100(14):8424-9. PMC: 166245. DOI: 10.1073/pnas.1431692100. View

12.

Soussi T, Leroy B, Devir M, Rosenberg S . High prevalence of cancer-associated TP53 variants in the gnomAD database: A word of caution concerning the use of variant filtering. Hum Mutat. 2019; 40(5):516-524. DOI: 10.1002/humu.23717. View

13.

Soussi T, Taschner P, Samuels Y . Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications. Hum Mutat. 2016; 38(4):339-342. DOI: 10.1002/humu.23163. View

14.

Hamroun D, Kato S, Ishioka C, Claustres M, Beroud C, Soussi T . The UMD TP53 database and website: update and revisions. Hum Mutat. 2005; 27(1):14-20. DOI: 10.1002/humu.20269. View

15.

Soussi T, Kato S, Levy P, Ishioka C . Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat. 2004; 25(1):6-17. DOI: 10.1002/humu.20114. View

16.

Ballinger M, Best A, Mai P, Khincha P, Loud J, Peters J . Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. JAMA Oncol. 2017; 3(12):1634-1639. PMC: 5824277. DOI: 10.1001/jamaoncol.2017.1968. View

17.

Rubin A, Green P . Mutation patterns in cancer genomes. Proc Natl Acad Sci U S A. 2009; 106(51):21766-70. PMC: 2799788. DOI: 10.1073/pnas.0912499106. View

18.

Raphael B, Dobson J, Oesper L, Vandin F . Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. Genome Med. 2014; 6(1):5. PMC: 3978567. DOI: 10.1186/gm524. View

19.

Ashworth J, Bernard B, Reynolds S, Plaisier C, Shmulevich I, Baliga N . Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. Nucleic Acids Res. 2014; 42(21):12973-83. PMC: 4245936. DOI: 10.1093/nar/gku1031. View

20.

Kastenhuber E, Lowe S . Putting p53 in Context. Cell. 2017; 170(6):1062-1078. PMC: 5743327. DOI: 10.1016/j.cell.2017.08.028. View